Does the media refer more to AMN or BAX?

In the previous week, AMN Healthcare Services had 9 more articles in the media than Baxter International. MarketBeat recorded 11 mentions for AMN Healthcare Services and 2 mentions for Baxter International. Baxter International's average media sentiment score of 0.89 beat AMN Healthcare Services' score of 0.19 indicating that Baxter International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Baxter International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DVA or BAX?

In the previous week, DaVita had 8 more articles in the media than Baxter International. MarketBeat recorded 10 mentions for DaVita and 2 mentions for Baxter International. DaVita's average media sentiment score of 1.25 beat Baxter International's score of 0.89 indicating that DaVita is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DXCM or BAX?

In the previous week, DexCom had 32 more articles in the media than Baxter International. MarketBeat recorded 34 mentions for DexCom and 2 mentions for Baxter International. DexCom's average media sentiment score of 1.09 beat Baxter International's score of 0.89 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 24 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RMD or BAX?

In the previous week, ResMed had 22 more articles in the media than Baxter International. MarketBeat recorded 24 mentions for ResMed and 2 mentions for Baxter International. ResMed's average media sentiment score of 1.04 beat Baxter International's score of 0.89 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 15 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STE or BAX?

In the previous week, STERIS had 11 more articles in the media than Baxter International. MarketBeat recorded 13 mentions for STERIS and 2 mentions for Baxter International. Baxter International's average media sentiment score of 0.89 beat STERIS's score of 0.71 indicating that Baxter International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Baxter International (BAX) Competitors

$19.24 -0.14 (-0.71%)

Closing price 03:59 PM Eastern

Extended Trading

$19.32 +0.07 (+0.37%)

As of 07:53 PM Eastern

Compare

BAX vs. AMN, DVA, DXCM, RMD, and STE

Should you buy Baxter International stock or one of its competitors? MarketBeat compares Baxter International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Baxter International include AMN Healthcare Services (AMN), DaVita (DVA), DexCom (DXCM), ResMed (RMD), and STERIS (STE). These companies are all part of the "medical" sector.

How does Baxter International compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Baxter International (NYSE:BAX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

AMN Healthcare Services has higher earnings, but lower revenue than Baxter International. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.44	-$95.70M	-$0.87	N/A
Baxter International	$11.24B	0.88	-$957M	-$2.13	N/A

AMN Healthcare Services has a net margin of -0.95% compared to Baxter International's net margin of -9.70%. AMN Healthcare Services' return on equity of 18.01% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Baxter International	-9.70%	16.15%	5.24%

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by company insiders. Comparatively, 0.2% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AMN Healthcare Services has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

In the previous week, AMN Healthcare Services had 9 more articles in the media than Baxter International. MarketBeat recorded 11 mentions for AMN Healthcare Services and 2 mentions for Baxter International. Baxter International's average media sentiment score of 0.89 beat AMN Healthcare Services' score of 0.19 indicating that Baxter International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Baxter International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services presently has a consensus target price of $25.29, indicating a potential downside of 18.25%. Baxter International has a consensus target price of $19.73, indicating a potential upside of 2.52%. Given Baxter International's higher possible upside, analysts clearly believe Baxter International is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Summary

AMN Healthcare Services beats Baxter International on 9 of the 16 factors compared between the two stocks.

How does Baxter International compare to DaVita?

DaVita (NYSE:DVA) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

90.1% of DaVita shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 1.5% of DaVita shares are held by insiders. Comparatively, 0.2% of Baxter International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, DaVita had 8 more articles in the media than Baxter International. MarketBeat recorded 10 mentions for DaVita and 2 mentions for Baxter International. DaVita's average media sentiment score of 1.25 beat Baxter International's score of 0.89 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DaVita has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

DaVita currently has a consensus price target of $199.17, suggesting a potential upside of 3.82%. Baxter International has a consensus price target of $19.73, suggesting a potential upside of 2.52%. Given DaVita's stronger consensus rating and higher possible upside, research analysts plainly believe DaVita is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

DaVita has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.90	$746.80M	$10.78	17.80
Baxter International	$11.24B	0.88	-$957M	-$2.13	N/A

DaVita has a net margin of 5.65% compared to Baxter International's net margin of -9.70%. Baxter International's return on equity of 16.15% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Baxter International	-9.70%	16.15%	5.24%

Summary

DaVita beats Baxter International on 13 of the 16 factors compared between the two stocks.

How does Baxter International compare to DexCom?

DexCom (NASDAQ:DXCM) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

DexCom has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Baxter International has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

97.8% of DexCom shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.2% of Baxter International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DexCom has a net margin of 19.31% compared to Baxter International's net margin of -9.70%. DexCom's return on equity of 33.33% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Baxter International	-9.70%	16.15%	5.24%

In the previous week, DexCom had 32 more articles in the media than Baxter International. MarketBeat recorded 34 mentions for DexCom and 2 mentions for Baxter International. DexCom's average media sentiment score of 1.09 beat Baxter International's score of 0.89 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	24 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom presently has a consensus price target of $83.04, suggesting a potential upside of 8.38%. Baxter International has a consensus price target of $19.73, suggesting a potential upside of 2.52%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts plainly believe DexCom is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

DexCom has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.34	$836.30M	$2.34	32.74
Baxter International	$11.24B	0.88	-$957M	-$2.13	N/A

Summary

DexCom beats Baxter International on 16 of the 17 factors compared between the two stocks.

How does Baxter International compare to ResMed?

ResMed (NYSE:RMD) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. ResMed pays out 23.1% of its earnings in the form of a dividend. Baxter International pays out -1.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

ResMed has a net margin of 27.44% compared to Baxter International's net margin of -9.70%. ResMed's return on equity of 25.35% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Baxter International	-9.70%	16.15%	5.24%

In the previous week, ResMed had 22 more articles in the media than Baxter International. MarketBeat recorded 24 mentions for ResMed and 2 mentions for Baxter International. ResMed's average media sentiment score of 1.04 beat Baxter International's score of 0.89 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	15 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ResMed has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.45	$1.40B	$10.37	18.65
Baxter International	$11.24B	0.88	-$957M	-$2.13	N/A

ResMed presently has a consensus price target of $286.18, indicating a potential upside of 48.01%. Baxter International has a consensus price target of $19.73, indicating a potential upside of 2.52%. Given ResMed's stronger consensus rating and higher possible upside, research analysts plainly believe ResMed is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Summary

ResMed beats Baxter International on 17 of the 20 factors compared between the two stocks.

How does Baxter International compare to STERIS?

STERIS (NYSE:STE) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, STERIS had 11 more articles in the media than Baxter International. MarketBeat recorded 13 mentions for STERIS and 2 mentions for Baxter International. Baxter International's average media sentiment score of 0.89 beat STERIS's score of 0.71 indicating that Baxter International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. STERIS pays out 31.8% of its earnings in the form of a dividend. Baxter International pays out -1.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years. STERIS is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a net margin of 13.18% compared to Baxter International's net margin of -9.70%. Baxter International's return on equity of 16.15% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Baxter International	-9.70%	16.15%	5.24%

STERIS has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.46	$782.30M	$7.93	26.51
Baxter International	$11.24B	0.88	-$957M	-$2.13	N/A

STERIS presently has a consensus price target of $278.00, indicating a potential upside of 32.26%. Baxter International has a consensus price target of $19.73, indicating a potential upside of 2.52%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

94.7% of STERIS shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.2% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

STERIS has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Summary

STERIS beats Baxter International on 15 of the 19 factors compared between the two stocks.

Get Baxter International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BAX vs. The Competition

Export

Metric	Baxter International	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$10.01B	$8.48B	$6.49B	$23.05B
Dividend Yield	0.21%	2.52%	2.67%	4.10%
P/E Ratio	-9.03	16.16	23.92	30.30
Price / Sales	0.88	7.13	507.55	22.44
Price / Cash	3.41	17.45	26.99	18.46
Price / Book	1.62	3.55	10.28	4.61
Net Income	-$957M	$225.32M	$3.57B	$1.07B
7 Day Performance	4.53%	-1.06%	-1.43%	-1.80%
1 Month Performance	7.10%	2.21%	3.27%	-1.21%
1 Year Performance	-36.43%	-3.10%	23.37%	21.30%

Baxter International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BAX Baxter International	1.4888 of 5 stars	$19.24 -0.7%	$19.73 +2.5%	-36.0%	$10.01B	$11.24B	N/A	37,500
AMN AMN Healthcare Services	1.6742 of 5 stars	$29.47 +1.7%	$25.29 -14.2%	+50.7%	$1.12B	$2.73B	N/A	2,664	Analyst Revision
DVA DaVita	4.3398 of 5 stars	$190.28 -2.1%	$199.17 +4.7%	+39.4%	$12.48B	$13.64B	17.65	78,000	Positive News
DXCM DexCom	4.2779 of 5 stars	$74.87 +1.5%	$82.42 +10.1%	-15.9%	$28.45B	$4.66B	32.00	11,000	Positive News Analyst Forecast Insider Trade
RMD ResMed	4.8426 of 5 stars	$186.58 -2.1%	$286.18 +53.4%	-22.3%	$27.64B	$5.15B	17.99	10,600	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BAX) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Baxter International (BAX) Competitors

BAX vs. AMN, DVA, DXCM, RMD, and STE

How does Baxter International compare to AMN Healthcare Services?

Summary

How does Baxter International compare to DaVita?

Summary

How does Baxter International compare to DexCom?

Summary

How does Baxter International compare to ResMed?

Summary

How does Baxter International compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAX vs. The Competition

Baxter International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Baxter International (BAX) Competitors

BAX vs. AMN, DVA, DXCM, RMD, and STE

How does Baxter International compare to AMN Healthcare Services?

Which has stronger earnings and valuation, AMN or BAX?

Is AMN or BAX more profitable?

Do insiders & institutionals have more ownership in AMN or BAX?

Which has more volatility and risk, AMN or BAX?

Does the media refer more to AMN or BAX?

Do analysts recommend AMN or BAX?

Summary

How does Baxter International compare to DaVita?

Do institutionals & insiders hold more shares of DVA or BAX?

Does the media refer more to DVA or BAX?

Which has more volatility & risk, DVA or BAX?

Do analysts recommend DVA or BAX?

Which has preferable earnings & valuation, DVA or BAX?

Is DVA or BAX more profitable?

Summary

How does Baxter International compare to DexCom?

Which has more risk and volatility, DXCM or BAX?

Do insiders and institutionals have more ownership in DXCM or BAX?

Is DXCM or BAX more profitable?

Does the media prefer DXCM or BAX?

Do analysts rate DXCM or BAX?

Which has stronger earnings and valuation, DXCM or BAX?

Summary

How does Baxter International compare to ResMed?

Is RMD or BAX a better dividend stock?

Is RMD or BAX more profitable?

Does the media favor RMD or BAX?

Which has more volatility & risk, RMD or BAX?

Do insiders and institutionals hold more shares of RMD or BAX?

Which has preferable earnings & valuation, RMD or BAX?

Do analysts recommend RMD or BAX?

Summary

How does Baxter International compare to STERIS?

Does the media refer more to STE or BAX?

Is STE or BAX a better dividend stock?

Is STE or BAX more profitable?

Which has better earnings and valuation, STE or BAX?

Do analysts recommend STE or BAX?

Do insiders & institutionals believe in STE or BAX?

Which has more risk and volatility, STE or BAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAX vs. The Competition

Baxter International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools